Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPL 2009-0031

Next Previous
Search
Drug Profile

CPL 2009-0031

Alternative Names: CPL-2009-0031

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cadila Pharmaceuticals
  • Class Amides; Antihyperglycaemics; Antihypoglycaemics; Fluorobenzenes; Piperazines; Triazoles
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus(In volunteers, In adults) in India (PO, Tablet)
  • 25 Jul 2022 CPL 2009-0031 is still in phase III trials for Type-2 diabetes mellitus (Treatment-experienced) in India (PO, Tablet) (Cadila Pharmaceuticals pipeline, July 2022)
  • 11 Feb 2021 Cadila Pharmaceuticals completes a phase III trial in Type-2 diabetes mellitus (Treatment-experienced) in India (PO, Tablet) (CTRI2019-04-018763) (NCT04801199)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top